USFDA Warning | Lupin Sees Marginal Impact on Earnings; Resolution to Take 12-15 Mths | CNBC TV18

CHART BUSTER | Lupin's Pithampur Unit 1 Receives EIR from USFDA | CNBC TV18Подробнее

Lupin | The Stock on the Radar | Pharma Stock in Focus | CNBC TV18Подробнее

Lupin Slips In Trade As U.S FDA Issues Warning Letter For Tarapur Facility | ChartbustersПодробнее

US FDA Concerns Hit Lupin HardПодробнее

US FDA Warning Letter On LUPIN's Goa Plant | Power Breakfast | Business News | CNBC-TV18Подробнее

Lupin Slumps Post Weak Q1 Performance | Profit Misses Estimates, Margins Contract | #1QWithCNBCTV18Подробнее

US FDA Issues 3 Observations To Lupin’s Pithampur Unit 3Подробнее

U.S FDA Commences Inspections Of Lupin And Aurobindo Pharma's Facilities | Halftime ReportПодробнее

Resolution Will Take Time: LupinПодробнее

Lupin Drops After USFDA Warning | Traders Hotline | 7th Nov | CNBC AwaazПодробнее

Torrent Pharma's Gujarat Facility Gets U.S FDA Observation, Lupin's Tarapur Unit Gets Warning LetterПодробнее

Lupin Finally Makes Its Observations PublicПодробнее

US Drug Regulator Issues Six Observations To Lupin's Indore PlantПодробнее

Lupin Management Speaks On The Co's Q4FY23 Earnings & India And US Biz Updates | Halftime ReportПодробнее

Lupin: US FDA Inspection at Nagpur Plant to Start Today | CNBC TV18Подробнее

Lupin Sees Licensing Income Of Rs 210 Cr In Q3Подробнее

Lupin's USFDA compliance woes points to system wide remediation | Reporter's TakeПодробнее

Lupin Gets FDA's Nod For Asthma Drug gSpiriva | CNBC TV18Подробнее